なぜ、あえて、「GLP1ダイエット外来を設けたのですか？」とか、「iryoo.jpというプラットフォームを創ったのですか？」と、周囲の人に聞かれることがあります。今日、届いたメールの中には、その答えがありました。

回答は、海外の医学レベルに、少しでも近づくためです。ぜひ、以下の英語をお読みください。Diabesityは、Diabetes + Obesity でしたが、Metabesity は、Metabolic Syndrome + Obesity という略語のようです。糖尿病の治療薬、治療概念は長寿にまで応用できるとあります。digital technologyは、それを支援します。

Dear Yoshihiko,

As someone who shares my passion for fighting diabetes, you would be interested in the science and technology of not only reducing risk of type 2 diabetes, but also lowering risks of other metabolically-driven chronic diseases and the aging process itself. Growing evidence points to diabetes, cardiovascular and neurodegenerative diseases, cancer, and the aging process as sharing metabolic causes that can be targeted with interventions that reduce risks of all these conditions. Putting a name—Metabesity—on this constellation of age-related chronic diseases is intended to catalyze broad-based R&D of approaches aimed at the shared metabolic drivers of all these conditions.

As an example, metformin, a drug we all know well and I approved while I was at FDA, is about to be tested in a major trial—Targeting Aging with Metformin. TAME aims to show that risk of a composite of myocardial infarction, stroke, heart failure hospitalization, dementia, and cancer can be reduced. Thus, the goal of TAME is to demonstrate that healthspan, the period of life free of chronic diseases, can be increased. Solutions for Metabesity are not just drugs, but includes any suitable intervention, such as digital technology, nutritional products, lifestyle, and social and educational approaches. You may be surprised by the progress of geroscience in yielding candidates for increasing healthspan and slowing the aging process.

I invite you to learn more about Metabesity, healthspan, and the prospects of slowing the aging process by attending the October virtual conference, Targeting Metabesity 2020 (www.metabesity2020.com), which will bring together leading global experts and stakeholders. There is no charge for attending. Feel free to contact me directly if you have interest in joining the moonshot project of targeting Metabesity.

To your health!

-Zan

Alexander Fleming, M.D.
Co-Founder of The Kitalys Institute
zanfleming@kitalys.org
www.kitalys.org